{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:57Z","timestamp":1789013457215,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T00:00:00Z","timestamp":1406332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA98413-09"],"award-info":[{"award-number":["CA98413-09"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA98543-09"],"award-info":[{"award-number":["CA98543-09"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Children and adolescents with <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>urkitt <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ymphoma (<jats:styled-content style=\"fixed-case\">BL<\/jats:styled-content>) and combined central nervous system (<jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (\u226525% blasts) and\/or <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\u2010positive <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>urkitt lymphoma the chemoimmunotherapy combination of rituximab (375\u00a0mg\/m<jats:sup>2<\/jats:sup>) and the standard chemotherapy arm of our previously reported <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>rench\u2010<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>merican\u2010<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ritish (<jats:styled-content style=\"fixed-case\">FAB<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ymphome <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>alins de <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>urkitt (<jats:styled-content style=\"fixed-case\">LMB<\/jats:styled-content>) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content> disease\u00a0\u00b1\u00a0leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3\u2010year event\u2010free survival (<jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>)\/overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) was 90% (95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>], 76\u201396%) in the entire cohort and 93% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 61\u201399%) in patients with <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content> disease. Based on the results of this trial, an international randomized study of <jats:styled-content style=\"fixed-case\">FAB<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LMB<\/jats:styled-content> 96 chemotherapy\u00a0\u00b1\u00a0rituximab for high\u2010risk patients is currently under investigation.<\/jats:p>","DOI":"10.1111\/bjh.13040","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T07:48:02Z","timestamp":1406360882000},"page":"394-401","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow\u2010positive <scp>B<\/scp>urkitt lymphoma\/leukaemia: a Children's Oncology Group Report"],"prefix":"10.1111","volume":"167","author":[{"given":"Stanton","family":"Goldman","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology Medical City Children's Hospital Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Biostatistics College of Public Health University of Nebraska Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Galardy","sequence":"additional","affiliation":[{"name":"Department Pediatric Hematology\/Oncology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie L.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Kimble","family":"Frazer","sequence":"additional","affiliation":[{"name":"Section of Pediatric Hematology\u2010Oncology University of Oklahoma Health Sciences Center Oklahoma City OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Sanger","sequence":"additional","affiliation":[{"name":"Center for Human Genetics University of Nebraska Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics College of Public Health University of Nebraska Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Gross","sequence":"additional","affiliation":[{"name":"Center for Global Health National Cancer Institute National Institute of Health Rockville MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology Massachusetts General Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Pediatrics New York Medical College Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Shiramizu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology University of Hawaii Honolulu HI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics New York Medical College Valhalla NY USA"},{"name":"Department of Medicine New York Medical College Valhalla NY USA"},{"name":"Department of Pathology New York Medical College Valhalla NY USA"},{"name":"Department of Microbiology and Immunology New York Medical College Valhalla NY USA"},{"name":"Department of Cell Biology and Anatomy New York Medical College Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12434"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3369"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08947.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01965.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12542"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255"},{"key":"e_1_2_7_12_1","first-page":"1","article-title":"The natural duration of cancer","volume":"33","author":"Greenwood M.","year":"1926","journal-title":"Reports on Public Health and Medical Subjects"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086827"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_7_15_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy S.B.","year":"1980","journal-title":"Seminars in Oncology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.312"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1636"},{"key":"e_1_2_7_20_1","volume-title":"ISCN 2005: An International System for Human Cytogenetic Nomenclature","author":"Shaffer L.G.","year":"2005"},{"key":"e_1_2_7_21_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13040","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:10:52Z","timestamp":1696317052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,26]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1111\/bjh.13040"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13040","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,26]]},"assertion":[{"value":"2014-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}